Argentinian guidelines for similar biological medicines

Home/Guidelines | Posted 03/05/2013 post-comment0 Post your comment

The regulatory body for approval of medicines in Argentina is the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (National Administration of Drugs, Foods and Medical Devices; ANMAT).

ANMAT logo V13E03

The agency was created in August 1992 by decree 1490/92 and it is responsible for the quality of drugs, foodstuff, medicinal products, diagnosis reagents, cosmetic products, dietary supplements and household cleaning products. The agency is also responsible for the authorization, registration, standardization, vigilance and monitoring of the products used in the human medicine, food and cosmetic fields.

In Argentina, a draft guideline for biosimilars, or medicamento biológico similar (similar biological medicines) as they are referred to in Argentina, was issued in July 2008 by ANMAT [1].

Overarching Guideline
This guideline covers all similar biological medicines:

Registration and registry modification of biological medicinal products
Date: July 2008

The guideline allows for an abbreviated licensing pathway for similar biological medicines and is based on the European model [2].

The guideline defines a similar biological medicine as a medicinal product that has been shown, by similarity studies, to be similar in terms of quality, safety, and efficacy to a biological medicinal product taken as reference which has already been authorized by the health authority. The present definition is applicable to those products that may be broadly characterized, such as proteins obtained by recombinant DNA techniques and polypeptides and highly purified natural proteins.

Editor’s comment
It should be noted that similar biological medicines approved in Argentina might not have been authorized following as strict a regulatory process as is required for biosimilars in the EU. EMA regulatory requirements ensure the same high standards of quality, safety and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product.

Related articles

Prospects for producing follow-on biological products in Brazil

EU guidelines for biosimilars


1.  GaBI Online - Generics and Biosimilars Initiative. Global biosimilars guideline development – EGA’s perspective []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 3]. Available from:

2.  GaBI Online - Generics and Biosimilars Initiative. Biosimilars dilemma over reference products []. Mol, Belgium: Pro Pharma Communications International; [cited 2013 May 3]. Available from:

Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: ANMAT, EGA

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010